Sherlock Biosciences, Inc., a biotechnology company, develops molecular diagnostics solutions. It offers SHERLOCK, a CRISPR-based method to detect and quantify specific genetic sequences, and INSPECTR, a synthetic biology-based molecular diagnostics platform. The company offers its products in the areas of precision oncology, infection identification, food safety, at-home tests, and disease detection. The company was incorporated in 2018 and is based in Cambridge, Massachusetts.
Stilla Technologies is a Paris-based European Biotechnology company that focuses on accelerating the development of next-generation genetic tests by providing a ground-breaking and flexible digital PCR (dPCR) solution: the Naica System. Taking advantage of cutting-edge microfluidic innovations, Stilla aims to make dPCR a lab commodity to all Life Sciences areas: research, therapeutics, and all the “omics”.
DNA Script SAS, founded in 2014 and based in Paris, France, specializes in synthetic biology tools and innovative DNA synthesis technology. The company has developed a groundbreaking enzymatic technology that powers the SYNTAX, the world's first benchtop DNA printer. This device allows laboratories to produce synthetic oligonucleotides on-site, significantly enhancing workflow control and expediting access to results. By employing an efficient biochemical process for nucleic acid synthesis, DNA Script enables researchers to rapidly generate essential genomic materials, such as oligonucleotides, which are crucial for genomics and molecular biology applications. Through its advancements, DNA Script aims to facilitate breakthroughs in life sciences and human health.
Genome Medical, Inc. is a national telegenomics company that specializes in providing genetic consultation and medical consulting services. Incorporated in 2016 and based in South San Francisco, California, the company utilizes its Genome Care Delivery technology platform to deliver genetic solutions across various clinical areas, including cancer, cardiovascular health, reproductive health, pediatrics, and pharmacy. By leveraging a nationwide network of genetic specialists, Genome Medical offers expert virtual genetic care to individuals and families, enhancing their health and well-being. The company also assists healthcare providers and patients in navigating the expanding field of genetics, enabling them to interpret test results, assess disease risk, expedite diagnoses, make informed treatment choices, and reduce healthcare costs.
DNA Script SAS, founded in 2014 and based in Paris, France, specializes in synthetic biology tools and innovative DNA synthesis technology. The company has developed a groundbreaking enzymatic technology that powers the SYNTAX, the world's first benchtop DNA printer. This device allows laboratories to produce synthetic oligonucleotides on-site, significantly enhancing workflow control and expediting access to results. By employing an efficient biochemical process for nucleic acid synthesis, DNA Script enables researchers to rapidly generate essential genomic materials, such as oligonucleotides, which are crucial for genomics and molecular biology applications. Through its advancements, DNA Script aims to facilitate breakthroughs in life sciences and human health.
Encoded Therapeutics, Inc. is a biotechnology company focused on developing precision gene therapies for severe genetic disorders. The company's innovative platform identifies sequences within the human genome that regulate gene expression through advanced screening and computational methods. Its therapy pipeline targets a variety of genetic and acquired disorders across multiple disease pathways, including neurocircuitry, liver and metabolic disorders, neurodegeneration, and cardiovascular diseases. Founded in 2014 and headquartered in South San Francisco, California, Encoded Therapeutics aims to enhance treatment options available to medical practitioners, ultimately improving patient outcomes and quality of life.
Genome Medical, Inc. is a national telegenomics company that specializes in providing genetic consultation and medical consulting services. Incorporated in 2016 and based in South San Francisco, California, the company utilizes its Genome Care Delivery technology platform to deliver genetic solutions across various clinical areas, including cancer, cardiovascular health, reproductive health, pediatrics, and pharmacy. By leveraging a nationwide network of genetic specialists, Genome Medical offers expert virtual genetic care to individuals and families, enhancing their health and well-being. The company also assists healthcare providers and patients in navigating the expanding field of genetics, enabling them to interpret test results, assess disease risk, expedite diagnoses, make informed treatment choices, and reduce healthcare costs.
Stilla Technologies is a biotechnology company based in Villejuif, France, with an additional location in Beverly, Massachusetts. Founded in 2013, the company specializes in accelerating the development of next-generation genetic tests through its innovative digital PCR solution, the Naica System. This platform leverages advanced microfluidic technologies to enhance the accessibility and efficiency of genetic testing across various life sciences fields, including research and therapeutics. Stilla Technologies aims to simplify the polymerase chain reaction process, offering a flexible and user-friendly system that supports multiple chemistries and multiplex capabilities. By providing tools for high-resolution genetic analysis, the company empowers researchers to conduct more intuitive image analysis and data exploration.
At Cradle Genomics, their mission is to provide knowledge that helps every pregnancy. They're dedicated to the transformation of non-invasive prenatal testing (NIPT) by offering the most comprehensive fetal genetic analysis and pregnancy health screening solutions at the earliest stages of pregnancy.
Cradle Genomics is newly formed with their headquarters based in San Diego and additional R&D operations located in Detroit. Cradle tests are based on the genetic analysis of fetal cells that are quickly collected during a first trimester visit with no risk to the mother or developing fetus.
Encoded Therapeutics, Inc. is a biotechnology company focused on developing precision gene therapies for severe genetic disorders. The company's innovative platform identifies sequences within the human genome that regulate gene expression through advanced screening and computational methods. Its therapy pipeline targets a variety of genetic and acquired disorders across multiple disease pathways, including neurocircuitry, liver and metabolic disorders, neurodegeneration, and cardiovascular diseases. Founded in 2014 and headquartered in South San Francisco, California, Encoded Therapeutics aims to enhance treatment options available to medical practitioners, ultimately improving patient outcomes and quality of life.
DNA Script SAS, founded in 2014 and based in Paris, France, specializes in synthetic biology tools and innovative DNA synthesis technology. The company has developed a groundbreaking enzymatic technology that powers the SYNTAX, the world's first benchtop DNA printer. This device allows laboratories to produce synthetic oligonucleotides on-site, significantly enhancing workflow control and expediting access to results. By employing an efficient biochemical process for nucleic acid synthesis, DNA Script enables researchers to rapidly generate essential genomic materials, such as oligonucleotides, which are crucial for genomics and molecular biology applications. Through its advancements, DNA Script aims to facilitate breakthroughs in life sciences and human health.
LunaPBC, Inc. operates a community-owned platform focused on health and DNA research. The company offers LunaDNA, a database that facilitates the sharing of health and genetic data for medical research. This platform supports health research initiatives by both non-profit and for-profit organizations, contributing to medical discoveries. LunaPBC operates as a Public Benefit Corporation, emphasizing community welfare by allowing individuals to share their health data, which in turn drives research and innovation. Additionally, members of the platform have the opportunity to share in the earnings derived from medical advancements, promoting a sense of shared ownership and benefit within the community. Founded in 2017 and based in San Diego, California, LunaPBC aims to advance genomic and medical research while prioritizing the interests of its contributors.
LunaDNA is a community-owned platform that facilitates the sharing of health and DNA data for medical research. Founded by the creators of Illumina, a leader in DNA sequencing, LunaDNA addresses the issue of siloed genomic data by providing individuals with a compelling incentive to share their health information. Participants are rewarded with shares in the database, allowing them to benefit from the profits generated by medical research and discoveries. This model not only empowers users to contribute their health records, genomic data, and personal health experiences but also fosters a sense of community ownership. As researchers pay to access the data for their studies, the proceeds are distributed back to the community, akin to dividends. By prioritizing privacy and trust, LunaDNA aims to increase participation in genomic research while facilitating advancements in healthcare that can ultimately save lives.
Stilla Technologies is a Paris-based European Biotechnology company that focuses on accelerating the development of next-generation genetic tests by providing a ground-breaking and flexible digital PCR (dPCR) solution: the Naica System. Taking advantage of cutting-edge microfluidic innovations, Stilla aims to make dPCR a lab commodity to all Life Sciences areas: research, therapeutics, and all the “omics”.
LunaDNA is a community-owned platform that facilitates the sharing of health and DNA data for medical research. Founded by the creators of Illumina, a leader in DNA sequencing, LunaDNA addresses the issue of siloed genomic data by providing individuals with a compelling incentive to share their health information. Participants are rewarded with shares in the database, allowing them to benefit from the profits generated by medical research and discoveries. This model not only empowers users to contribute their health records, genomic data, and personal health experiences but also fosters a sense of community ownership. As researchers pay to access the data for their studies, the proceeds are distributed back to the community, akin to dividends. By prioritizing privacy and trust, LunaDNA aims to increase participation in genomic research while facilitating advancements in healthcare that can ultimately save lives.
Genome Medical, Inc. is a national telegenomics company that specializes in providing genetic consultation and medical consulting services. Incorporated in 2016 and based in South San Francisco, California, the company utilizes its Genome Care Delivery technology platform to deliver genetic solutions across various clinical areas, including cancer, cardiovascular health, reproductive health, pediatrics, and pharmacy. By leveraging a nationwide network of genetic specialists, Genome Medical offers expert virtual genetic care to individuals and families, enhancing their health and well-being. The company also assists healthcare providers and patients in navigating the expanding field of genetics, enabling them to interpret test results, assess disease risk, expedite diagnoses, make informed treatment choices, and reduce healthcare costs.
LunaDNA is a community-owned platform that facilitates the sharing of health and DNA data for medical research. Founded by the creators of Illumina, a leader in DNA sequencing, LunaDNA addresses the issue of siloed genomic data by providing individuals with a compelling incentive to share their health information. Participants are rewarded with shares in the database, allowing them to benefit from the profits generated by medical research and discoveries. This model not only empowers users to contribute their health records, genomic data, and personal health experiences but also fosters a sense of community ownership. As researchers pay to access the data for their studies, the proceeds are distributed back to the community, akin to dividends. By prioritizing privacy and trust, LunaDNA aims to increase participation in genomic research while facilitating advancements in healthcare that can ultimately save lives.
DNA Script SAS, founded in 2014 and based in Paris, France, specializes in synthetic biology tools and innovative DNA synthesis technology. The company has developed a groundbreaking enzymatic technology that powers the SYNTAX, the world's first benchtop DNA printer. This device allows laboratories to produce synthetic oligonucleotides on-site, significantly enhancing workflow control and expediting access to results. By employing an efficient biochemical process for nucleic acid synthesis, DNA Script enables researchers to rapidly generate essential genomic materials, such as oligonucleotides, which are crucial for genomics and molecular biology applications. Through its advancements, DNA Script aims to facilitate breakthroughs in life sciences and human health.
Genome Medical, Inc. is a national telegenomics company that specializes in providing genetic consultation and medical consulting services. Incorporated in 2016 and based in South San Francisco, California, the company utilizes its Genome Care Delivery technology platform to deliver genetic solutions across various clinical areas, including cancer, cardiovascular health, reproductive health, pediatrics, and pharmacy. By leveraging a nationwide network of genetic specialists, Genome Medical offers expert virtual genetic care to individuals and families, enhancing their health and well-being. The company also assists healthcare providers and patients in navigating the expanding field of genetics, enabling them to interpret test results, assess disease risk, expedite diagnoses, make informed treatment choices, and reduce healthcare costs.
Human Longevity (HLI) is a health intelligence company focused on advancing proactive healthcare through genomic insights. Founded in 2013 and based in San Diego, HLI utilizes a comprehensive database of genomic and phenotypic data, combined with machine learning, to enhance medical practices and foster discoveries in health. The company’s primary offerings include the HLI Health Nucleus, a clinical research center that integrates whole-genome sequencing, advanced imaging, and personalized health data to provide a detailed view of individual health. HLI also addresses significant health issues, such as cancer, diabetes, obesity, heart and liver diseases, and dementia, by leveraging DNA sequencing and expert analysis. Through its innovative approach, HLI aims to improve health outcomes and transition healthcare from reactive to proactive strategies.
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company’s DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has a collaboration agreement with ImmunoPrecise Antibodies Ltd. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company’s DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has a collaboration agreement with ImmunoPrecise Antibodies Ltd. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.
Desktop Genetics is an international biotechnology company established in 2012 to help researchers discover and treat the root genetic causes of human disease. Today, Desktop Genetics is a recognised leader in genome editing technology, staffed by dedicated team of genome editing experts, bioinformaticians and data scientists, driven by the real-world impact of CRISPR technology. They have invested four years developing their core technology, DESKGEN AI, trained on the largest database of genome editing data in the world. DESKGEN AI powers their flagship DESKGEN CRISPR Library product range, which enables the work of their pharma, biotech and academic customers working in drug discovery and functional genomics. Desktop Genetics' tools and technologies are used by over 1800 organisations all over the world, and their projects contribute directly to several key partnerships to bring CRISPR into the clinic. The company has received awards from Fast Company, Kairos 50 and SxSW Interactive.
23andMe, Inc. is a consumer genetics company that provides DNA analysis services through home-based saliva collection kits, enabling users to explore their ancestry, inherited traits, and health insights. Founded in 2006 and headquartered in Sunnyvale, California, the company offers various services, including Health + Ancestry and Ancestry + Traits, which provide insights into a person's genetic background and over 30 trait reports. 23andMe aims to help individuals understand the implications of their genetic information while also catering to researchers by offering categorized and searchable data. The company was co-founded by Linda Avey and Anne Wojcicki and has positioned itself as a significant player in the growing biotechnology and healthcare sectors.